Lepu Medical Technology (Beijing) Co., Ltd.

Shenzhen Stock Exchange 300003.SZ

Lepu Medical Technology (Beijing) Co., Ltd. Revenue for the year ending December 31, 2023: USD 1.12 B

Lepu Medical Technology (Beijing) Co., Ltd. Revenue is USD 1.12 B for the year ending December 31, 2023, a -26.89% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Lepu Medical Technology (Beijing) Co., Ltd. Revenue for the year ending December 31, 2022 was USD 1.54 B, a -8.36% change year over year.
  • Lepu Medical Technology (Beijing) Co., Ltd. Revenue for the year ending December 31, 2021 was USD 1.68 B, a 36.22% change year over year.
  • Lepu Medical Technology (Beijing) Co., Ltd. Revenue for the year ending December 31, 2020 was USD 1.23 B, a 10.01% change year over year.
  • Lepu Medical Technology (Beijing) Co., Ltd. Revenue for the year ending December 31, 2019 was USD 1.12 B, a 21.12% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
Shenzhen Stock Exchange: 300003.SZ

Lepu Medical Technology (Beijing) Co., Ltd.

CEO Dr. Zhongjie Pu
IPO Date Oct. 30, 2009
Location China
Headquarters 37 Chaoqian Road
Employees 10,652
Sector Health Care
Industries
Description

Lepu Medical Technology (Beijing) Co., Ltd. develops, produces, and sells medical devices and equipment. The company offers cardiovascular interventional products, such as coronary stents and balloons, catheters, guide wires, introducer sheaths, tourniquets, inflation devices, and PCI accessories; structural heart diseases products, including occluders, vascular plugs, delivery systems, and mechanical heart valves; cardiac rhythm management products, which include pacemakers, equipment, leads, and electrophysiology; off-pump coronary artery bypass grafting surgical cardiology products; and PTA balloons and guide wires peripheral interventional products. It also provides critical care products, such as vascular access products, needle free connectors, blood samplers, and pressure transducers; floor and suspended type digital subtraction angiography systems; in vitro diagnostic equipment and biomarkers; hemodialysis catheters and hollow fiber dialyzers; and general surgery products, including surgical staplers and endo surgery accessories. In addition, the company offers cardiovascular system drugs, such as antithrombotic, hypolipidemic, antihypertensive, antianginal, and heart failure treatment; ß-lactamase antibiotics and antifungal antimicrobial drugs; central nervous system drugs comprises painkillers and antidepressants; gastric/duodenal ulcer and chronic liver disease treatment drugs; respiratory system drugs; hypoproteinemia drugs; and activating blood circulation drugs. Further, it provides precision medicine, ECG telemonitoring, and cardiovascular disease consulting and management center services; medical S&T incubation and equity investment, and medical financial services; consultation, online pharmacy, and household medical equipment services; smart devices; and specialized hospital services for cardiovascular diseases, as well as involved in the co-construction of Cath lab. The company was founded in 1999 and is headquartered in Beijing, China.

Similar companies

300122.SZ

Chongqing Zhifei Biological Products Co., Ltd.

USD 3.45

3.36%

000963.SZ

Huadong Medicine Co., Ltd

USD 4.53

2.64%

300015.SZ

Aier Eye Hospital Group Co., Ltd.

USD 1.73

3.02%

002007.SZ

Hualan Biological Engineering Inc.

USD 2.17

2.25%

300124.SZ

Shenzhen Inovance Technology Co.,Ltd

USD 8.43

5.92%

StockViz Staff

January 16, 2025

Any question? Send us an email